IP Verse

Syringe - EP3685826

The patent EP3685826 was granted to Novartis on Nov 3, 2021. The application was originally filed on Jan 25, 2013 under application number EP20159408A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3685826

NOVARTIS
Application Number
EP20159408A
Filing Date
Jan 25, 2013
Status
Granted And Under Opposition
Oct 1, 2021
Publication Date
Nov 3, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSApr 28, 2023ELKINGTON AND FIFEINTERVENTION WITHDRAWN
BOEHMERT & BOEHMERT ANWALTSPARTNERSCHAFT MBBAug 3, 2022KUTTENKEULERADMISSIBLE
EHLERSAug 3, 2022EISENFUHR SPEISERADMISSIBLE
HAMM & WITTKOPPAug 3, 2022HAMM & WITTKOPPWITHDRAWN
HOFFMANN EITLEAug 2, 2022HOFFMANN EITLEWITHDRAWN
KEIL & SCHAAFHAUSEN PATENTANWALTE PARTGMBBAug 1, 2022KEIL & SCHAAFHAUSEN PATENTANWALTE PARTGMBBWITHDRAWN
WITHERS & ROGERSJul 29, 2022TOMBLINGADMISSIBLE

Patent Citations (65) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP1767546
DESCRIPTIONWO2010060748
DESCRIPTIONWO2011135067
OPPOSITIONAU2012101677
OPPOSITIONAU2012101678
OPPOSITIONAU2013100070
OPPOSITIONAU2013100071
OPPOSITIONDE102008005938
OPPOSITIONDE202012011016U
OPPOSITIONDE202012011259U
OPPOSITIONDE202012011260U
OPPOSITIONDE202013000688U
OPPOSITIONEP0738517
OPPOSITIONEP1488818
OPPOSITIONEP2047877
OPPOSITIONEP2298392
OPPOSITIONEP3381444
OPPOSITIONJP2001340455
OPPOSITIONJP2002177388
OPPOSITIONJP2004313369
OPPOSITIONJP2012045046
OPPOSITIONJPH0725953
OPPOSITIONUS2006293270
OPPOSITIONUS2007250017
OPPOSITIONUS2008262435
OPPOSITIONUS2008312607
OPPOSITIONUS2009010985
OPPOSITIONUS2010100054
OPPOSITIONUS2011257601
OPPOSITIONUS2011276005
OPPOSITIONUS2012078224
OPPOSITIONUS2012091026
OPPOSITIONUS4184593
OPPOSITIONUS4946441
OPPOSITIONUS5405326
OPPOSITIONUS5688252
OPPOSITIONUS5795337
OPPOSITIONUS6090081
OPPOSITIONUS7060269
OPPOSITIONUSD430015S
OPPOSITIONWO2004075958
OPPOSITIONWO2007035621
OPPOSITIONWO2007035623
OPPOSITIONWO2007149334
OPPOSITIONWO2008077155
OPPOSITIONWO2008154630
OPPOSITIONWO2009030975
OPPOSITIONWO2009030976
OPPOSITIONWO2009099641
OPPOSITIONWO2009158613
OPPOSITIONWO2011006877
OPPOSITIONWO2011059823
OPPOSITIONWO2012117837
OPPOSITIONWO2013045571
OPPOSITIONWO2013151904
OPPOSITIONWO2013178771
OPPOSITIONWO2013184270
OPPOSITIONWO9744068
OTHERUS6090081
OTHERWO2011059823
OTHERWO2014005728
SEARCHDE102008005938
SEARCHUS2006293270
SEARCHUS2011257601
SEARCHWO2007035621

Non-Patent Literature (NPL) Citations (102) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BADKAR et al., AAPS PharmaSciTech, (20110000), vol. 12, no. 2, pages 564 - 572
DESCRIPTION- DAYHOFF et al., Atlas of Protein Sequence and Structure, (19780000), vol. 5
DESCRIPTION- HOLASH et al., PNAS USA, (20020000), vol. 99, pages 11393 - 98
DESCRIPTION- LI et al., Molecular Vision, (20110000), vol. 17, pages 797 - 803
DESCRIPTION- RIELYMILLER, Clin Cancer Res, (20070000), vol. 13, pages 4623 - 7
DESCRIPTION- SMITHWATERMAN, Adv. Appl. Math., (19810000), vol. 2, pages 482 - 489
EXAMINATION- L. Liu ET AL, "Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab: Effects of Long-term Storage and Product Mishandling", Investigative Ophthalmology & Visual Science, (20110222), vol. 52, no. 2, doi:10.1167/iovs.10-6431, ISSN 0146-0404, pages 1023 - 1034, XP055059283
OPPOSITION- "3.2.8 Sterile Einmalspritzen aus Kunststoff", Ph.Eur. 7. Ausgabe Grundwerk, (20110101), pages 522 - 523, XP055642513
OPPOSITION- Adler Micheal, "Challenges in the Development of Pre-filled Syringes for Biologics from a Formulation Scientist's Point of View", American Pharmaceutical Review, (20120201), pages 1 - 7, American Pharmaceutical Review, (20220816), XP055951840
OPPOSITION- Adler Micheal, "Challenges in the Development of Pre-filled Syringes for Biologics from a Formulation Scientist's Point of View", American Pharmaceutical Review, (20120201), pages 1 - 7, XP055951840
OPPOSITION- "Aflibercept injection for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD)", Division of Transplant and Ophthalmology Products Advisory Committee Meeting Briefing Package, (20110619), pages 1 - 70, URL: http://web.archive.org/web/20110619002211if_/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM259142.pdf, XP055951074
OPPOSITION- AKERS MICHAEL J; VASUDEVAN VASU; STICKELMEYER MARY, "FORMULATION DEVELOPMENT OF PROTEIN DOSAGE FORMS.", PHARMACEUTICAL BIOTECHNOLOGY, KLUWER, DORDRECHT, NL, NL , (20020101), vol. 14, ISSN 1078-0467, pages 47 - 127, XP001537612
OPPOSITION- Anonymous, "3.2.8 Sterile Einmalspritzen aus Kunststoff", Ph.Eur. 7. Ausgabe Grundwerk, (20110101), pages 522 - 523, XP055642513
OPPOSITION- Anonymous, "(788) PARTICULATE MATTER IN INJECTIONS / PHYSICAL TESTS", USP34 NF 29 U.S. PHARMACOPEIA NATIONAL FORMULARY, (20110101), vol. 1, pages 328 - 329, XP055952532
OPPOSITION- Anonymous, "ADVANCEMENTS IN PREFILLED SYRINGE TECHNOLOGY: IMPROVING COMPATIBILITY WITH BIOLOGICS WITH A NOVEL CROSS-LINKED SILI- CONE COATING", INJECTABLE DRUG DELIVERY 2012: DEVICES FOCUS, (20120630), pages 1 - 8, XP055951917
OPPOSITION- Anonymous, "Aflibercept injection for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD)", Division of Transplant and Ophthalmology Products Advisory Committee Meeting Briefing Package, (20110619), pages 1 - 70, Division of Transplant and Ophthalmology Products Advisory Committee Meeting Briefing Package , URL: http://web.archive.org/web/20110619002211if_/http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DermatologicandOphthalmicDrugsAdvisoryCommittee/UCM259142.pdf, (20220812), XP055951074
OPPOSITION- Anonymous, "Components for prefilled syringes", DATWYLER, (20111001), DATWYLER, URL: https://datwyler.com, (20240205), XP093127167
OPPOSITION- Anonymous, "Division of Transplant and Ophthalmology Products Advisory Committee Meeting Briefing Package", DTOP - Aflibercept Briefing Package for Advisory Meeting, (20170000), pages 1 - 70, XP055951939
OPPOSITION- Anonymous, "Division of Transplant and Ophthalmology Products Advisory Committee Meeting Briefing Package", DTOP - Aflibercept Briefing Package for Advisory Meeting, (20170101), pages 1 - 70, DTOP - Aflibercept Briefing Package for Advisory Meeting, (20220816), XP055951939
OPPOSITION- anonymous, "Einsteiger-Einführung zur Partikeltechnik", PARTICLE MEASURING SYSTEMS, URL: https://www.pmeasuring.com/PMS/files/52/52c21a84-8f8f-4de6-be7c-a3fda327f85a.pdf
OPPOSITION- Anonymous, "Fachinformation Novartis Pharma Lucentis®", (20070101), pages 1 - 5, XP055889817
OPPOSITION- Anonymous, "FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe ", Press Release Regeneron Pharmaceuticals Inc., (20190813), Press Release Regeneron Pharmaceuticals Inc., URL: https://newsroom.regeneron.com/news-releases/news-release-details/fda-approves-eylear-aflibercept-injection-prefilled-syringe, (20220812), XP055951079
OPPOSITION- Anonymous, "FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema - European Pharmaceutical Review", (20120813), URL: https://www.europeanpharmaceuticalreview.com/news/14197/fda-approves-lucentis-ranibizumab-injection-for-treatment-of-diabetic-macular-edema/, (20220812), XP055951105
OPPOSITION- Anonymous, "Fokus IT IT meets Processes / ECV: TechnoPharm ", Internet Archive Wayback Machine, (20120930), pages 1 - 3, Internet Archive Wayback Machine , URL: https://web.archive.org/web/20120930082206/https://www.ecv.de/technopharm.php, (20220819), XP055952959
OPPOSITION- Anonymous, "FOKUS Lager und Logistik Lagerkonzepte: Vorteile und Anforderungen einer chaotischen Lagerung in der pharmazeutischen Industrie /ECV: TechnoPharm ", Internet Archive Wayback Machine, (20120511), pages 1 - 3, Internet Archive Wayback Machine , URL: https://web.archive.org/web/20120511034210/https://www.ecv.de/technopharm.php, (20220819), XP055952961
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION- LUCENTISâ„¢ (ranibizumab injection)", Genentech, Inc., (20060101), pages 1 - 7, Genentech, Inc.,, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf, (20191114), XP055642530
OPPOSITION- Anonymous, "Intelligent TDD via a selective barrier membrane", Drug Delivery Technology, (20090500), vol. 9, no. 5, pages 1 - 8, XP055951845
OPPOSITION- Anonymous, "Kanulenrohre aus nicht rostendem Stahl zur Herstellun Medizinprodukten (ISO 9626:1991+Amd.1:2001) (enthal Anderung A1:2001); Deutsche Fassung EN ISO 9626:1995+A1:2001, Berichtigung zu DIN EN ISO 9626:2002-03", DIN EN ISO 9626 Berichtigung 1, (20130101), pages 1 - 12, XP055952550
OPPOSITION- Anonymous, "Macugen Official FDA information, side effects and uses.", Internet Archive Wayback Machine, (20110307), pages 1 - 10, Internet Archive Wayback Machine , URL: https://web.archive.org/web/20110307065238/http://www.drugs.com:80/pro/macugen.html, (20220818), XP055952542
OPPOSITION- Anonymous, "Particle Counting in Injectable Solutions 2007 Updates", Particle Measuring Systems, Inc., (20070101), page 6pp, XP055642519
OPPOSITION- Anonymous, "Physical Tests/ (789) Particulate Matter in Ophthalmic Solutions", The United States Pharmacopeia USP 31. National Formulary NF 26, (20080501), pages 2pp, 313 - 314, XP055642492
OPPOSITION- Anonymous, "Physical Tests/ (789) Particulate Matter in Ophthalmic Solutions", The United States Pharmacopeia USP 35, (20111202), pages 342 - 343, XP055897740
OPPOSITION- Anonymous, "Prefilled syringe Part 4:Glass barrels for injectables Seringues préremplies Partie 4: Cylindres en verre pour produits injectables", ISO11040-4 (2007), (20070201), XP093127170
OPPOSITION- Anonymous, "Prefilled syringes Part 5: Plunger stoppers for injectables", ISO 11040-5, (20011215), XP093127177
OPPOSITION- Anonymous, "Prefilled syringes- Part 6 : Plastic barrels for injectables", International standard : ISO 11040-6: 2012 (E), (20120401), pages ii-iv, 1 - 10, XP055642502
OPPOSITION- Anonymous, "PRODUCT INFORMATION EYLEA® aflibercept (rch)", Australian Register of Therapeutic Goods, (20120307), pages 1 - 18, XP055642472
OPPOSITION- Anonymous, "SCHOTT TopPac® Polymer Prefillable Syringes", Schott AG, (20070329), pages 1 - 24, XP055952544
OPPOSITION- Anonymous, "Sterile Einmalspritzen fUr medizinische Zwecke Teil 1 : Spritzen zum manuellen Gebrauch", DIN EN ISO 7886-1, (19971001), DIN EN ISO 7886-1, (20180719), XP055493706
OPPOSITION- Anonymous, "Sterile Einmalspritzen fUr medizinische Zwecke Teil 1 : Spritzen zum manuellen Gebrauch", DIN EN ISO 7886-1, (19971001), XP055493706
OPPOSITION- Anonymous, "USP 789: Particulate Matter in Ophthalmic Solutions", Physical Tests, (20120000), page 789, URL: https://www.drugfuture.com/Pharmacopoeia/usp35/PARTICULATEMATERINOPHTHALMICSOLUTIONS.pdf, XP055899216
OPPOSITION- Anonymous, "Vorgefüllte Spritzen Teil 4: Spritzenzylinder aus Glas für Injektionspräparate", Deutsche Norm Din ISO 11040-4, (19960801), pages 1 - 5, XP055642494
OPPOSITION- Anonymous, "West Introduces The Daikyo Crystal Zenith RU Prefillable Syringe System", PHARMACEUTICAL ONLINE, (20080625), pages 1 - 1, PHARMACEUTICAL ONLINE, (20220826), XP055955238
OPPOSITION- Arno Fries, "Drug delivery of sensitive biopharmaceuticals with prefilled syringes", Drug Delivery Technology, (20090101), vol. 9, no. 5, pages 22 - 27, XP055952517
OPPOSITION- Bernie Lehandro, "The next generation of ready-to-use prefillable syringes: first in silicone-free solutions", PREFILLED SYRINGES: THE CONTAINER OF CHOICE FOR TODAY’S INJECTABLES, ONdrugDelivery Ltd, UK, UK , (20080101), pages 24 - 26, PREFILLED SYRINGES: THE CONTAINER OF CHOICE FOR TODAY’S INJECTABLES, URL: http://www.ondrugdelivery.com/publications/prefilled_syringes_2008.pdf, (20170511), XP055371894
OPPOSITION- Böttger Frank, "More than Filling - New Developments in Siliconization and Silicone Layer Analytics", Bio Production Forum Fill and Finish for Biopharmaceuticals., (20100615), pages 1 - 43, XP055642524
OPPOSITION- BÖTTGER, "New Developments in Siliconization and Silicone Layer Analytics", Bio Production Forum, (20100600), XP055642524
OPPOSITION- Bruno Reuter et al, "Syringe Siliconization Trends, methods, analysis procedures", (20120101), URL: https://pdfs.semanticscholar.org/e940/10e357b30dd015752cb005c15e14fa7dd506.pdf?_ga=2.180808103.1640326775.1579172132-188552557.1579172132, (20200116), XP055658634
OPPOSITION- Bruno Reuter; Petersen Claudia; Gerresheimer Bünde; Gmbh; Bünde, "Syringe Siliconization Trends, methods, analysis procedures", TechnoPharm, (20120801), vol. 2, no. 4, pages 238 - 244, XP055658634
OPPOSITION- Bruno Reuter, Petersen Claudia, "Syringe Siliconization Trends, methods, analysis procedures", TechnoPharm, (20120101), vol. 2, no. 4, pages 238 - 244, XP055658634
OPPOSITION- D104 - A signed statement by Neil Cammish
OPPOSITION- D105 - 5 A letter to the EPO in respect of EP19210117.8 and dated 5th November 2020
OPPOSITION- "Division of Transplant and Ophthalmology Products Advisory Committee Meeting", Briefing Package, XP055951074
OPPOSITION- Ema, "Avastin 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung Bevacizumab", Gebrauchsinformation: Information für Anwender, (20221201), pages 1 - 11, Gebrauchsinformation: Information für Anwender, (20240205), XP093127173
OPPOSITION- "EYLEA® aflibercept (rch)", PRODUCT INFORMATION, (20120307), pages 1 - 18, XP055642472
OPPOSITION- "FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe ", Press Release Regeneron Pharmaceuticals Inc., (20190813), URL: https://newsroom.regeneron.com/news-releases/news-release-details/fda-approves-eylear-aflibercept-injection-prefilled-syringe, XP055951079
OPPOSITION- "FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema - European Pharmaceutical Review", (20120813), URL: https://www.europeanpharmaceuticalreview.com/news/14197/fda-approves-lucentis-ranibizumab-injection-for-treatment-of-diabetic-macular-edema/, XP055951105
OPPOSITION- Frank Böttger, "More than Filling. New Developments in Siliconization and Silicone Layer Analytics", Bio Production Forum - Fill and Finish for Biopharmaceuticals, (20100601), pages 1 - 43, XP055642524
OPPOSITION- Frank Bottger, "More than Filling. New Developments in Siliconization and Silicone Layer Analytics", Bio Production Forum - Fill and Finish for Biopharmaceuticals, (20100651), pages 1 - 43, XP055642524
OPPOSITION- FRIES, Drug Delivery of sensitive Biopharmaceuticals with prefilled syringes, (20090000), XP055952517
OPPOSITION- Gerding H., Timmermann M., "Accuracy and Precision of Intravitreally Injected Ranibi- zumab Doses: An Experimental Study ", Klin Monatsbl Augenheilkd, (20100101), vol. 227, pages 269 - 272, XP055952540
OPPOSITION- HIOBIK, "Reducing Quality Risks to Drug Products and Meeting Needs of Patients with Enhanced Components for Prefilled Syringe Systems", proceedings, XP093004158
OPPOSITION- Hlobik, Et Al, "Prefilled Syringes: The Future of Injection Safety starts here", ONdrugdelivery, (20120101), vol. 30, pages 1 - 44, XP055955233
OPPOSITION- James A. Dixon, Oliver S; Olson J L; Mandava N, "VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration", Expert Opinion on Investigational Drugs, (20091001), vol. 18, no. 10, pages 1573 - 1580, XP055952523
OPPOSITION- "Lucentis®", Fachinformation Novartis Pharma, (20070101), pages 1 - 5, XP055889817
OPPOSITION- "LUCENTISâ„¢ (ranibizumab injection)", HIGHLIGHTS OF PRESCRIBING INFORMATION, (20060101), pages 1 - 7, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/125156lbl.pdf, XP055642530
OPPOSITION- Malvern Instruments Limited, "A basic guide to particle characterization", Malvern Instruments Limited, (20150101), pages 1 - 24, XP055906696
OPPOSITION- Mintz C., "Prefilled syringes: The Next "Big Thing"", Bioprocess Online, (20120830), URL: https://www.bioprocessonline.com/doc/prefilled-syringes-the-next-big-thing-0001, XP002788671
OPPOSITION- Mintz C., "Prefilled syringes: The Next "Big Thing"", Bioprocess Online, (20120930), Bioprocess Online, URL: https://www.bioprocessonline.com/doc/prefilled-syringes-the-next-big-thing-0001, (20190206), XP002788671
OPPOSITION- N Clunas, Sigg J, Boado L, Momm J, Weber C, Alete D, Peregi E, Picci M, "RANIBIZUMAB PRE-FILLED SYRINGE: RECENTLY APPROVED INNOVATION IN THE EUROPEAN UNION WITH THE POTENTIAL TO REDUCE INFECTION RISK, IMPROVE DOSE ACCURACY, AND ENHANCE EFFICIENT TREATMENT ADMINISTRATION", 5th World Congress on Controversies in Ophthalmology (COPHY), (20140320), 5th World Congress on Controversies in Ophthalmology (COPHY), URL: http://comtecmed.com/COPHY/2014/Uploads/Editor/Group%20A/17.pdf, (20191101), XP055638316
OPPOSITION- N Clunas, Sigg J, Boado L, Momm J, Weber C, Alete D, Peregi E, Picci M, "RANIBIZUMAB PRE-FILLED SYRINGE: RECENTLY APPROVED INNOVATION IN THE EUROPEAN UNION WITH THE POTENTIAL TO REDUCE INFECTION RISK, IMPROVE DOSE ACCURACY, AND ENHANCE EFFICIENT TREATMENT ADMINISTRATION", 5th World Congress on Controversies in Ophthalmology (COPHY), (20140320), XP055638316
OPPOSITION- Particle Measuring Systems, Inc., "Particle Counting in Injectable Solutions 2007 Updates", (20070101), page 6pp, XP055642519
OPPOSITION- "Prefilled syringes- Part 6 : Plastic barrels for injectables", International standard : ISO 11040-6: 2012 (E), (20120401), pages ii-iv, 1 - 10, XP055642502
OPPOSITION- REUTER B, PETERSEN C, "Syringe siliconisation", TechnoPharm, Editio Cantor Verlag, DE, DE , (20120101), vol. 2, no. 4, ISSN 2191-8341, pages 238 - 244, XP002725465
OPPOSITION- REUTER et al., "Syringe Siliconization", TechnoPharm, (20120000), vol. 2, no. 4, pages 238 - 244, XP055658634
OPPOSITION- SCHOENKNECHT T.P. ET AL, "REQUIREMENTS ON PRE-FILLABLE GLASS SYRINGES", AAPS NATIONAL BIOTECHNOLOGY CONFERENCE, (20070627), page 1, XP003035654
OPPOSITION- Sebastien Jouffray, "ADVANCEMENTS IN PREFILLED SYRINGE TECHNOLOGY: IMPROVING COMPATIBILITY WITH BIOLOGICS WITH A NOVEL CROSS-LINKED SILICONE COATING", Injectable Drug Delivery 2012: Devices Focus, (20120601), pages 4 - 8, Injectable Drug Delivery 2012: Devices Focus, URL: https://www.ondrugdelivery.com/wp-content/uploads/2018/11/JunJul2012.pdf, (20210106), XP055762947
OPPOSITION- Sebastien Jouffray, "ADVANCEMENTS IN PREFILLED SYRINGE TECHNOLOGY: IMPROVING COMPATIBILITY WITH BIOLOGICS WITH A NOVEL CROSS-LINKED SILICONE COATING", Injectable Drug Delivery 2012: Devices Focus, (20120601), pages 4 - 8, URL: https://www.ondrugdelivery.com/wp-content/uploads/2018/11/JunJul2012.pdf, XP055762947
OPPOSITION- Shah Bhavnesh D, Prajapati Bhupendra G., "Pre-Filled Syringes: A New Concept", Pharma Bio World, (20090801), pages 51 - 57, XP055951125
OPPOSITION- "Sterile Einmalspritzen fUr medizinische Zwecke Teil 1 : Spritzen zum manuellen Gebrauch", DIN EN ISO 7886-1, (19971001), XP055493706
OPPOSITION- T. P. SCHOENKNECHT, "Requirements on pre-fillable glass syringes", AAPS NATIONAL BIOTECHNOLOGY CONFERENCE, (20070000), page 1, XP003035654
OPPOSITION- T, P. SCHOENKNECHT, "Requirements on pre-fillable glass syringes", AAPS National Biotechnology Conference, (2007), XP003035654
OPPOSITION- "Vorgefüllte Spritzen Teil 4: Spritzenzylinder aus Glas für Injektionspräparate", Deutsche Norm Din ISO 11040-4, (19960801), pages 1 - 5, XP055642494
OPPOSITION- Wagner Andrea, "Advances in Prefilled Syringe Technology Developments in areas such as component materials, surface treatments and filling processes are continuing to boost the appeal of prefilled syringes and expand their use with many of today's parenteral products", Innovations in Pharmaceutical Technology, (20070101), vol. 24, pages 73 - 75, XP093127181
OPPOSITION- FUNKE et al., "Analysis of thin baked-on silicone layers by FTIR and 3D- Laser Scanning Microscopy", European Journal of Pharmaceutics and Biopharmaceutics, (20150000), vol. 96, doi:10.1016/j.ejpb.2015.08.009, pages 304 - 313, XP055642550
OPPOSITION- Stefanie Funke, Et Al.,, "Analysis of thin baked-on silicone layers by FTIR and 3D-Laser Scanning Microscopy", European Journal of Pharmaceutics and Biopharmaceutics, (20150101), vol. 96, doi:10.1016/j.ejpb.2015.08.009, pages 304 - 313, XP055642550
OPPOSITION- JOUBERT, "Classification and Characterization of Therapeutic Antibody Aggregates", The journal of biological chemistry, (20110715), vol. 286, doi:10.1074/jbc.M110.160457, pages 25118 - 25133, XP055650027
OPPOSITION- BAKRI et al., "Intravitreal silicone oil droplets after intravitreal drug injections", Retina, (20080700), vol. 28, no. 7, doi:10.1097/IAE.0b013e31816c6868, pages 996 - 1001, XP055186525
OPPOSITION- B AKRI et al., "Intravitreal silicone oil droplets after intravitreal drug injections", Retina, vol. 28, no. 7, doi:10.1097/IAE.0b013e31816c6868, pages 996 - 1001, XP055186525
OPPOSITION- Bakri Et Al, "INTRAVITREAL SILICONE OIL DROPLETS AFTER INTRAVITREAL DRUG INJECTIONS", THE JOURNAL OF RETINAL AND VITREOUS DISEASES, doi:10.1097/IAE.0b013e31816c6868, (20080101), pages 996 - 1001, THE JOURNAL OF RETINAL AND VITREOUS DISEASES, URL: http://www.medlive.cn/pro/appeal/upload/newtranslate/1220343816678_115538.pdf, (20150429), XP055186525
OPPOSITION- Liu L; Ammar D A; Ross L A; Mandava N; Kahook M Y; Carpenter J F, "Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab: Effects of Long-term Storage and Product Mishandling", Investigative Ophthalmology & Visual Science, (20110222), pages 1023 - 1034, URL: https://iovs.arvojournals.org/arti- cle.aspx?articleid=2126227, XP055059283
OPPOSITION- L. Liu, D. A. Ammar, L. A. Ross, N. Mandava, M. Y. Kahook, J. F. Carpenter, "Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab: Effects of Long-term Storage and Product Mishandling", Investigative Ophthalmology & Visual Science, (20110222), vol. 52, no. 2, doi:10.1167/iovs.10-6431, ISSN 01460404, pages 1023 - 1034, XP055059283
OPPOSITION- L. Liu, D. A. Ammar, L. A. Ross, N. Mandava, M. Y. Kahook, J. F. Carpenter, "Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab: Effects of Long-term Storage and Product Mishandling", Investigative Ophthalmology & Visual Science, ¬Association for Research in Vision and Ophthalmology, etc.|, (20110222), vol. 52, no. 2, doi:10.1167/iovs.10-6431, ISSN 01460404, pages 1023 - 1034, XP055059283
OPPOSITION- Advait Badkar; Amanda Wolf; Leigh Bohack; Parag Kolhe, "Development of Biotechnology Products in Pre-filled Syringes: Technical Considerations and Approaches", AAPS PHARMSCITECH, Springer New York LLC, US, US , (20110504), vol. 12, no. 2, doi:10.1208/s12249-011-9617-y, ISSN 1530-9932, pages 564 - 572, XP019925550
OPPOSITION- Advait Badkar; Amanda Wolf; Leigh Bohack; Parag Kolhe, "Development of Biotechnology Products in Pre-filled Syringes: Technical Considerations and Approaches", AAPS PHARMSCITECH, US , (20110504), vol. 12, no. 2, doi:10.1208/s12249-011-9617-y, ISSN 1530-9932, pages 564 - 572, XP019925550
OPPOSITION- BADKAR et al., "Development of Biotechnology Products in Pre-filled Syringes: Technical Considerations and Approaches", AAPS PharmSciTech, (20110600), vol. 12, no. 2, XP019925550
OPPOSITION- CHAN, EDWIN et al., "Syringe Siliconization Process Investigation and Optimization", PDA Journal of Pharmaceutical Science and Technology, (20120000), vol. 66, no. 2, doi:10.5731/pdajpst.2012.00856, XP003035655
OPPOSITION- CHAN E, ET AL, "SYRINGE SILICONIZATION PROCESS INVESTIGATION AND OPTIMIZATION", PDA Journal of Pharmaceutical Science and Technology, Parenteral Drug Association, US, US , (20120101), vol. 66, doi:10.5731/pdajpst.2012.00856, ISSN 1079-7440, pages 136 - 150, XP003035655
OTHER- BERNIE LAHENDRO, "THE NEXT GENERATION OF READY-TO-USE PREFILLABLE SYRINGES: FIRST IN SILICONE-FREE SOLUTIONS", PREFILLED SYRINGES: THE CONTAINER OF CHOICE FOR TODAY'S INJECTABLES, (20080611), pages 24 - 26, URL: https://www.ondrugdelivery.com/wp-content/uploads/2018/11/Jun2008.pdf, XP055371894
OTHER- B. LAHENDRO, "The next generation of ready-to-use prefillable syringes: first in silicone-free solutions", PREFILLED SYRINGES: THE CONTAINER OF CHOICE FOR TODAY’S INJECTABLES, (20080000), pages 24 - 26, XP055371894
OTHER- SEBASTIEN JOUFFRAY, "ADVANCEMENTS IN PREFILLED SYRINGE TECHNOLOGY: IMPROVING COMPATIBILITY WITH BIOLOGICS WITH A NOVEL CROSS-LINKED SILICONE COATING", INJECTABLE DRUG DELIVERY 2012: DEVICES FOCUS, (20120630), pages 4 - 8, URL: https://www.ondrugdelivery.com/wp-content/uploads/2018/11/JunJul2012.pdf, XP055762947
OTHER- LU LIU, DAVID A. AMMAR, LINDSEY A. ROSS, NARESH MANDAVA, MALIK Y. KAHOOK, JOHN F. CARPENTER, "Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab: Effects of Long-term Storage and Product Mishandling", Investigative Ophthalmology & Visual Science, (20110200), vol. 52, no. 2, pages 1023 - 1034, XP055059283
OTHER- LU LIU et al., "Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab: Effects of Long-term Storage and Product Mishandling", Investigative Ophthalmology & Visual Science, (20110200), vol. 52, no. 2, pages 1023 - 1034, XP055059283

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents